clinical trial · NCT04944290
To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
Glaucoma, Open-AngleOcular HypertensionBrinzolamide/brimonidine ophthalmic suspensionSimbrinza 0.2%/1% Ophthalmic Suspension
brief summary
To compare the efficacy and safety of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
started
May 28, 2021
primary completion
Mar 11, 2022
completion
Jun 21, 2022
last updated
Apr 2, 2025
official title
Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide/Brimonidine Ophthalmic Suspension 1% to Simbrinza® in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol